|1.||Pietra, C: 3 articles (08/2003 - 07/2000)|
|2.||Villetti, G: 2 articles (08/2003 - 07/2000)|
|3.||Steardo, L: 2 articles (08/2001 - 07/2000)|
|4.||Kendrick, K M: 2 articles (08/2001 - 07/2000)|
|5.||Cassano, T: 2 articles (08/2001 - 07/2000)|
|6.||Trabace, L: 2 articles (08/2001 - 07/2000)|
|7.||Cuomo, V: 2 articles (08/2001 - 07/2000)|
|8.||Villetti, Gino: 1 article (05/2004)|
|9.||Stebel, Marco: 1 article (05/2004)|
|10.||Giannotta, Sabina: 1 article (05/2004)|
|1.||Amnesia (Dissociative Amnesia)
|2.||Alzheimer Disease (Alzheimer's Disease)
08/10/2001 - "Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels."
07/01/2000 - "These findings suggest that the anti-amnestic properties of CHF2819, together with its stimulatory effect on cholinergic and serotonergic functions, might have a therapeutic potential mainly for the symptomatic treatment of Alzheimer's disease patients in which the cognitive impairment is accompanied by a depressive syndrome."
05/01/2003 - "The objective of this study was to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of five fixed doses of ganstigmine (CHF 2819) in patients with probable Alzheimer's disease (AD). "
01/01/2002 - "The neurochemical and behavioral profiles of CHF2819 suggest that this orally active novel AChEI could be of clinical interest for the treatment of Alzheimer-type dementia associated with multiple neurotransmitter abnormalities in the brain. "
01/01/2002 - "CHF2819 is a novel orally active acetylcholinesterase inhibitor (AChEI) developed for the treatment of Alzheimer's disease (AD). "
|3.||Body Weight (Weight, Body)
01/01/2002 - "Functional observational battery (FOB) screening demonstrated that CHF2819 (1.5 and 4.5 mg/kg p.o.) does not affect activity, excitability, autonomic, neuromuscular, and sensorimotor domains, as well as physiological endpoints (body weight and temperature). "
07/01/2000 - "Functional observational battery screening demonstrates that CHF2819 (1.5 and 4.5 mg/kg p.o.) does not affect activity, excitability, autonomic, neuromuscular, and sensorimotor domains, as well as physiological end points (body weight and temperature). "
08/01/2003 - "Characterization of the effect of ganstigmine (CHF2819) on amyloid precursor protein metabolism in SH-SY5Y neuroblastoma cells."
08/01/2003 - "We have investigated the effect of ganstigmine (CHF2819), a novel geneserine derived acetylcholinesterase (AChE) inhibitor, on the expression and metabolism of the amyloid precursor protein (APP) in neuroblastoma cell line SH-SY5Y. "
|4.||Acetylcholine (Acetylcholine Chloride)
|5.||Neurotransmitter Agents (Neurotransmitter)
|6.||Amyloid (Amyloid Fibrils)